Sign In
Buy JNJ
Johnson & Johnson Earnings Calls
| Release date | Apr 14, 2026 |
| EPS estimate | $2.68 |
| EPS actual | $2.70 |
| EPS Surprise | 0.746% |
| Revenue estimate | 23.615B |
| Revenue actual | 24.062B |
| Revenue Surprise | 1.89% |
| Release date | Jan 21, 2026 |
| EPS estimate | $2.46 |
| EPS actual | $2.46 |
| Revenue estimate | 24.148B |
| Revenue actual | 24.564B |
| Revenue Surprise | 1.72% |
| Release date | Oct 14, 2025 |
| EPS estimate | $2.76 |
| EPS actual | $2.80 |
| EPS Surprise | 1.45% |
| Revenue estimate | 23.755B |
| Revenue actual | 23.993B |
| Revenue Surprise | 1.00% |
| Release date | Jul 16, 2025 |
| EPS estimate | $2.68 |
| EPS actual | $2.77 |
| EPS Surprise | 3.36% |
| Revenue estimate | 22.854B |
| Revenue actual | 23.743B |
| Revenue Surprise | 3.89% |
Last 4 Quarters for Johnson & Johnson
Below you can see how JNJ performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 16, 2025 |
| Price on release | $164.78 |
| EPS estimate | $2.68 |
| EPS actual | $2.77 |
| EPS surprise | 3.36% |
| Date | Price |
|---|---|
| Jul 10, 2025 | $157.69 |
| Jul 11, 2025 | $156.90 |
| Jul 14, 2025 | $156.82 |
| Jul 15, 2025 | $155.17 |
| Jul 16, 2025 | $164.78 |
| Jul 17, 2025 | $162.98 |
| Jul 18, 2025 | $163.70 |
| Jul 21, 2025 | $164.36 |
| Jul 22, 2025 | $167.93 |
| 4 days before | 4.50% |
| 4 days after | 1.91% |
| On release day | -1.09% |
| Change in period | 6.49% |
| Release date | Oct 14, 2025 |
| Price on release | $190.85 |
| EPS estimate | $2.76 |
| EPS actual | $2.80 |
| EPS surprise | 1.45% |
| Date | Price |
|---|---|
| Oct 08, 2025 | $189.69 |
| Oct 09, 2025 | $191.08 |
| Oct 10, 2025 | $190.72 |
| Oct 13, 2025 | $190.90 |
| Oct 14, 2025 | $190.85 |
| Oct 15, 2025 | $191.17 |
| Oct 16, 2025 | $192.12 |
| Oct 17, 2025 | $193.22 |
| Oct 20, 2025 | $193.72 |
| 4 days before | 0.612% |
| 4 days after | 1.50% |
| On release day | 0.168% |
| Change in period | 2.12% |
| Release date | Jan 21, 2026 |
| Price on release | $218.01 |
| EPS estimate | $2.46 |
| EPS actual | $2.46 |
| Date | Price |
|---|---|
| Jan 14, 2026 | $218.55 |
| Jan 15, 2026 | $219.57 |
| Jan 16, 2026 | $218.66 |
| Jan 20, 2026 | $218.21 |
| Jan 21, 2026 | $218.01 |
| Jan 22, 2026 | $218.49 |
| Jan 23, 2026 | $220.14 |
| Jan 26, 2026 | $221.49 |
| Jan 27, 2026 | $224.44 |
| 4 days before | -0.247% |
| 4 days after | 2.95% |
| On release day | 0.220% |
| Change in period | 2.70% |
| Release date | Apr 14, 2026 |
| Price on release | $240.10 |
| EPS estimate | $2.68 |
| EPS actual | $2.70 |
| EPS surprise | 0.746% |
| Date | Price |
|---|---|
| Apr 08, 2026 | $241.30 |
| Apr 09, 2026 | $241.31 |
| Apr 10, 2026 | $238.46 |
| Apr 13, 2026 | $237.96 |
| Apr 14, 2026 | $240.10 |
| Apr 15, 2026 | $238.67 |
| Apr 16, 2026 | $234.54 |
| Apr 17, 2026 | $234.18 |
| Apr 20, 2026 | $230.69 |
| 4 days before | -0.497% |
| 4 days after | -3.92% |
| On release day | -0.596% |
| Change in period | -4.40% |
Johnson & Johnson Earnings Call Transcript Summary of Q1 2026
Johnson & Johnson reported a strong start to 2026 with Q1 operational sales up 6.4% (Worldwide sales $24.1B). Innovative Medicine grew 7.4% driven by oncology and immunology launches (notably DARZALEX, CARVYKTI, TECVAYLI, TALVEY, RYBREVANT, TREMFYA and newly launched ICOTYDE), while MedTech grew 4.6% led by cardiovascular, electrophysiology, Abiomed/Impella and Shockwave. Management raised full‑year operational sales guidance to +5.9%–6.9% (midpoint ~$100.2B) and modestly increased adjusted EPS guidance to $11.30–$11.50. Key commercial highlights: ICOTYDE launched day‑one with early strong demand ( ~1,500 prescriptions in early weeks) and is positioned as a potential major product; INLEXZO is showing rapid uptake after receiving a permanent J‑code; DARZALEX and TREMFYA remain major growth drivers. Margins were partially impacted by heavier launch investments, tariffs and mix; adjusted pretax operating margin is still expected to improve at least 50 bps in 2026. Cash and capital allocation: ~$22B cash, $55B debt (net debt ~$33B), Q1 free cash flow ~$1.5B with full‑year FCF target ~$21B; board approved a 3.1% dividend increase. Management reiterated line of sight to double‑digit revenue growth by the end of the decade, driven by the current portfolio, launches and MedTech catalysts (OTTAVA, VARIPULSE Pro, new PFA catheters) and noted orthopedics separation work continuing into 2027.
